303 related articles for article (PubMed ID: 15335406)
21. [The role of terlipressin in hepatorenal syndrome].
Forcellini S; Fabbian F
G Ital Nefrol; 2010; 27(5):469-76. PubMed ID: 20922678
[TBL] [Abstract][Full Text] [Related]
22. Midodrine in the prevention of hepatorenal syndrome type 2 recurrence: a case-control study.
Alessandria C; Debernardi-Venon W; Carello M; Ceretto S; Rizzetto M; Marzano A
Dig Liver Dis; 2009 Apr; 41(4):298-302. PubMed ID: 19158001
[TBL] [Abstract][Full Text] [Related]
23. Terlipressin inhibits in vivo aortic iNOS expression induced by lipopolysaccharide in rats with biliary cirrhosis.
Moreau R; Barrière E; Tazi KA; Lardeux B; Dargère D; Urbanowicz W; Poirel O; Chauvelot-Moachon L; Guimont MC; Bernuau D; Lebrec D
Hepatology; 2002 Nov; 36(5):1070-8. PubMed ID: 12395316
[TBL] [Abstract][Full Text] [Related]
24. Beneficial effects of terlipressin in prolonged pediatric cardiopulmonary resuscitation: a case series.
Matok I; Vardi A; Augarten A; Efrati O; Leibovitch L; Rubinshtein M; Paret G
Crit Care Med; 2007 Apr; 35(4):1161-4. PubMed ID: 17312566
[TBL] [Abstract][Full Text] [Related]
25. Terlipressin for hepatorenal syndrome: A meta-analysis of randomized trials.
Fabrizi F; Dixit V; Messa P; Martin P
Int J Artif Organs; 2009 Mar; 32(3):133-40. PubMed ID: 19440988
[TBL] [Abstract][Full Text] [Related]
26. Noradrenaline vs terlipressin in the treatment of type 2 hepatorenal syndrome: a randomized pilot study.
Ghosh S; Choudhary NS; Sharma AK; Singh B; Kumar P; Agarwal R; Sharma N; Bhalla A; Chawla YK; Singh V
Liver Int; 2013 Sep; 33(8):1187-93. PubMed ID: 23601499
[TBL] [Abstract][Full Text] [Related]
27. Terlipressin: an asset for hepatologists!
Sarin SK; Sharma P
Hepatology; 2011 Aug; 54(2):724-8. PubMed ID: 21735463
[No Abstract] [Full Text] [Related]
28. Terlipressin Plus Albumin Is More Effective Than Albumin Alone in Improving Renal Function in Patients With Cirrhosis and Hepatorenal Syndrome Type 1.
Boyer TD; Sanyal AJ; Wong F; Frederick RT; Lake JR; O'Leary JG; Ganger D; Jamil K; Pappas SC;
Gastroenterology; 2016 Jun; 150(7):1579-1589.e2. PubMed ID: 26896734
[TBL] [Abstract][Full Text] [Related]
29. Targeting circulatory dysfunction in cirrhosis: terlipressin and the hepatorenal syndrome.
Testro AG; Angus PW
J Gastroenterol Hepatol; 2009 Nov; 24(11):1707-9. PubMed ID: 20136956
[No Abstract] [Full Text] [Related]
30. Terlipressin therapy with and without albumin for patients with hepatorenal syndrome: results of a prospective, nonrandomized study.
Ortega R; Ginès P; Uriz J; Cárdenas A; Calahorra B; De Las Heras D; Guevara M; Bataller R; Jiménez W; Arroyo V; Rodés J
Hepatology; 2002 Oct; 36(4 Pt 1):941-8. PubMed ID: 12297842
[TBL] [Abstract][Full Text] [Related]
31. The effects of vasopressin and its analogues on the liver and its disorders in the critically ill.
Asfar P; Radermacher P; Calès P; Oberti F
Curr Opin Crit Care; 2010 Apr; 16(2):148-52. PubMed ID: 20019608
[TBL] [Abstract][Full Text] [Related]
32. Results of pretransplant treatment of hepatorenal syndrome with terlipressin.
Solà E; Cárdenas A; Ginès P
Curr Opin Organ Transplant; 2013 Jun; 18(3):265-70. PubMed ID: 23652609
[TBL] [Abstract][Full Text] [Related]
33. Terlipressin: a promising vasoactive agent in hemodynamic support of septic shock.
Morelli A; Ertmer C; Pietropaoli P; Westphal M
Expert Opin Pharmacother; 2009 Oct; 10(15):2569-75. PubMed ID: 19735216
[TBL] [Abstract][Full Text] [Related]
34. Terlipressin and albumin in patients with cirrhosis and type I hepatorenal syndrome.
Neri S; Pulvirenti D; Malaguarnera M; Cosimo BM; Bertino G; Ignaccolo L; Siringo S; Castellino P
Dig Dis Sci; 2008 Mar; 53(3):830-5. PubMed ID: 17939047
[TBL] [Abstract][Full Text] [Related]
35. Terlipressin improves renal function in patients with cirrhosis and ascites without hepatorenal syndrome.
Krag A; Møller S; Henriksen JH; Holstein-Rathlou NH; Larsen FS; Bendtsen F
Hepatology; 2007 Dec; 46(6):1863-71. PubMed ID: 18027874
[TBL] [Abstract][Full Text] [Related]
36. Terlipressin Improves Renal Function and Reverses Hepatorenal Syndrome in Patients With Systemic Inflammatory Response Syndrome.
Wong F; Pappas SC; Boyer TD; Sanyal AJ; Bajaj JS; Escalante S; Jamil K;
Clin Gastroenterol Hepatol; 2017 Feb; 15(2):266-272.e1. PubMed ID: 27464593
[TBL] [Abstract][Full Text] [Related]
37. Terlipressin and hepatorenal syndrome: what is important for nephrologists and hepatologists.
Magan AA; Khalil AA; Ahmed MH
World J Gastroenterol; 2010 Nov; 16(41):5139-47. PubMed ID: 21049548
[TBL] [Abstract][Full Text] [Related]
38. Reversal of hepatorenal syndrome type 1 with terlipressin plus albumin vs. placebo plus albumin in a pooled analysis of the OT-0401 and REVERSE randomised clinical studies.
Sanyal AJ; Boyer TD; Frederick RT; Wong F; Rossaro L; Araya V; Vargas HE; Reddy KR; Pappas SC; Teuber P; Escalante S; Jamil K
Aliment Pharmacol Ther; 2017 Jun; 45(11):1390-1402. PubMed ID: 28370090
[TBL] [Abstract][Full Text] [Related]
39. Long-term outcome of patients treated with terlipressin for types 1 and 2 hepatorenal syndrome.
Testro AG; Wongseelashote S; Angus PW; Gow PJ
J Gastroenterol Hepatol; 2008 Oct; 23(10):1535-40. PubMed ID: 17784863
[TBL] [Abstract][Full Text] [Related]
40. Terlipressin in the treatment of hepatorenal syndrome: A systematic review and meta-analysis.
Wang H; Liu A; Bo W; Feng X; Hu Y
Medicine (Baltimore); 2018 Apr; 97(16):e0431. PubMed ID: 29668606
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
